KYMR Earnings & Financial Statements
Kymera Therapeutics, Inc.
$108.14
+$1.31(+1.23%)
43
Overall
45
Value
30
Tech
55
Quality
Market Cap
$8.88B
Volume
820.99K
52W Range
$55.26 - $130.05
Target Price
$138.58
KYMR earnings and financial statements: Kymera Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
KYMR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $39.21M | $47.07M | $78.59M | $46.83M | $72.83M |
| Operating income | -$349.40M | -$261.63M | -$165.53M | -$161.26M | -$100.53M |
| EBITDA | -$303.04M | -$216.49M | -$143.40M | -$151.66M | -$97.64M |
| Net income | -$311.35M | -$223.86M | -$146.96M | -$154.81M | -$100.22M |
| EPS (diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.74B | $978.03M | $575.76M | $603.13M | $605.90M |
| Total liabilities | $163.15M | $142.42M | $180.79M | $112.98M | $146.27M |
| Shareholders’ equity | $1.58B | $835.62M | $394.97M | $490.15M | $459.64M |
| Cash and equivalents | $357.01M | $120.26M | $109.97M | $68.39M | $47.98M |
| Long-term debt | $68.50M | $74.65M | $78.33M | $13.39M | $14.36M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$232.89M | -$194.50M | -$102.83M | -$153.09M | -$128.95M |
| Capital expenditure | -$1.45M | -$12.84M | -$34.48M | -$2.84M | -$1.60M |
| Free cash flow | -$234.34M | -$207.34M | -$137.31M | -$155.92M | -$130.54M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KYMR | $108.14 | +1.2% | 820.99K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Kymera Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW